^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yervoy (ipilimumab)

    i
    Other names: BMS-734016, MDX 101, MDX 010, MDX-CTLA-4, MDX-CTLA5, BMS734016, MDX-010, MDX010, BMS 734016
    Company:
    BMS, Ono Pharmaceutical
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    22h
    CheckMate 9DW: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Nov 2026 --> Jul 2026 | Trial primary completion date: Nov 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sorafenib • Lenvima (lenvatinib)
    1d
    PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Yervoy (ipilimumab) • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    3d
    Comparative efficacy and safety of nivolumab-based combination therapies (with ipilimumab or binimetinib) in patients with microsatellite-stable and microsatellite-instability-high metastatic colorectal cancer: a systematic review and meta-analysis. (PubMed, Clin Transl Oncol)
    In metastatic CRC patients who receive nivolumab-based combination therapies demonstrate partial tumor responses that increase while their safety profile remains acceptable, but their overall response rates do not improve. The research demonstrates how immunotherapy serves as a standard treatment method for MSI-H disease while emphasizing the need to develop biomarker-driven approaches that enhance treatment selection methods, especially for MSS CRC.
    Retrospective data • Review • Journal • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib)
    4d
    Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=30, Suspended, City of Hope Medical Center | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=18, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar) • Voyager-V1
    5d
    VT3989-001: Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=434, Recruiting, Vivace Therapeutics, Inc | Trial completion date: Jun 2027 --> Mar 2030 | Trial primary completion date: Dec 2026 --> Nov 2029
    Trial completion date • Trial primary completion date
    |
    EGFR L858R
    |
    Opdivo (nivolumab) • Tagrisso (osimertinib) • Yervoy (ipilimumab) • carboplatin • pemetrexed • VT3989
    5d
    A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) (clinicaltrials.gov)
    P1, N=35, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jul 2026 --> Mar 2026
    Enrollment open • Trial initiation date • First-in-human
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • HC-7366
    5d
    BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Brown University | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    6d
    Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling. (PubMed, Expert Opin Biol Ther)
    It discusses the major trials of nivolumab, pembrolizumab, and ipilimumab, including combinations from the CheckMate-142 and CheckMate-8HW trials. The combination of PD-1 and CTLA-4 inhibitors in MSI-H/dMMR metastatic colorectal cancer has demonstrated long-term clinical efficacy and a genuine survival benefit. However, in MSS metastatic colorectal cancer, there has been limited response, emphasizing the importance of innovative combination therapies to address both primary and secondary resistance.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    6d
    A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=49, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial • Tumor mutational burden
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Yervoy (ipilimumab) • Tafinlar (dabrafenib) • Tyvyt (sintilimab)
    6d
    ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab (clinicaltrials.gov)
    P4, N=90, Not yet recruiting, NYU Langone Health
    New P4 trial • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene) • IFNA1 (Interferon Alpha 1)
    |
    Signatera™
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    6d
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=825, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)